Regeneron Pharmaceuticals balance sheet

At the end of fiscal 2025, Regeneron Pharmaceuticals had total assets of $40.56bn, total liabilities of $9.30bn and shareholders' equity of $31.26bn. It held $3.12bn in cash against $1.99bn of debt: net cash of $1.13bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Regeneron Pharmaceuticals: balance sheet, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash and equivalents	0.2	0.1	0.5	0.2	0.5	0.6	0.8	0.5	0.8	1.5	1.6	2.2	2.9	3.1	2.7	2.5	3.1	3.7
Receivables	0.0	0.0	0.0	0.6	0.8	0.7	1.2	1.3	1.5	1.7	2.1	4.1	6.0	5.3	5.7	6.2	5.7	7.6
Inventory	—	—	0.0	0.0	0.1	0.1	0.2	0.4	0.7	1.2	1.4	1.9	2.0	2.4	2.6	3.1	3.2	2.9
Total current assets	0.4	0.4	0.7	1.2	1.8	2.1	2.9	3.2	4.3	6.4	7.7	9.8	14.0	15.9	19.5	18.7	18.0	20.8
Total assets	0.7	1.1	1.3	2.1	3.0	3.8	5.6	7.0	8.8	11.7	14.8	17.2	25.4	29.2	33.1	37.8	40.6	44.4
Accounts payable	—	—	—	—	—	—	—	—	0.2	0.2	0.4	0.5	0.6	0.6	0.6	0.8	0.9	1.1
Deferred revenue (current)	0.0	0.1	0.1	0.1	0.0	0.1	0.2	0.2	0.3	0.5	0.6	0.6	0.4	0.5	0.5	0.6	0.6	0.7
Total current liabilities	0.1	0.1	0.1	0.2	0.3	0.7	0.8	1.2	1.1	1.4	2.1	2.7	3.9	3.1	3.4	3.9	4.4	6.2
Short-term debt	—	—	—	—	—	—	—	—	—	—	0.0	—	—	—	—	—	—	—
Long-term debt	—	0.0	0.3	0.3	0.3	0.1	0.0	—	—	—	0.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Total debt	0.0	0.0	0.3	0.3	0.3	0.2	0.0	0.0	0.0	0.0	0.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Total liabilities	0.3	0.6	0.8	0.8	1.0	1.3	2.0	2.5	2.6	3.0	3.7	6.1	6.7	6.6	7.1	8.4	9.3	10.9
Shareholders' equity	0.4	0.5	0.5	1.3	2.0	2.6	3.7	4.4	6.1	8.8	11.1	11.0	18.8	22.7	26.0	29.4	31.3	33.5
Net debt (negative = net cash)	−0.2	−0.1	−0.2	0.1	−0.2	−0.5	−0.8	−0.5	−0.8	−1.5	−1.6	−0.2	−0.9	−1.1	−0.7	−0.5	−1.1	−1.7
Shares outstanding	79m	87m	91m	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

US$ billions unless shown otherwise. Fiscal quarters.

Regeneron Pharmaceuticals: balance sheet, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Receivables	6.2	5.6	5.6	5.7	5.7	5.7	6.6	7.6
Inventory	3.1	3.2	3.2	3.3	3.2	3.1	3.1	2.9
Total current assets	18.7	17.6	16.9	18.0	18.0	18.2	18.4	20.8
Total assets	37.8	37.5	38.2	40.2	40.6	40.9	41.7	44.4
Accounts payable	0.8	0.7	0.7	0.9	0.9	1.0	1.2	1.1
Deferred revenue (current)	0.6	0.6	0.5	0.5	0.6	0.6	0.7	0.7
Total current liabilities	3.9	3.6	3.7	4.4	4.4	5.1	5.5	6.2
Long-term debt	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Total debt	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Total liabilities	8.4	8.2	8.3	9.2	9.3	9.4	10.0	10.9
Shareholders' equity	29.4	29.4	29.9	31.0	31.3	31.4	31.7	33.5

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: REGN vs VRTX BIIB vs REGN GILD vs REGN AMGN vs REGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Regeneron Pharmaceuticals.